This company has been marked as potentially delisted and may not be actively trading. Amedica (AMDA) Competitors Add Compare Share Share Competitors Stock AnalysisCompetitorsTrendsBuy This Stock AMDA vs. PDEX, KRMD, CVRX, LUCD, LUNG, PROF, INFU, OBIO, ICAD, and MGRMShould you be buying Amedica stock or one of its competitors? The main competitors of Amedica include Pro-Dex (PDEX), KORU Medical Systems (KRMD), CVRx (CVRX), Lucid Diagnostics (LUCD), Pulmonx (LUNG), Profound Medical (PROF), InfuSystem (INFU), Orchestra BioMed (OBIO), iCAD (ICAD), and Monogram Orthopaedics (MGRM). Amedica vs. Pro-Dex KORU Medical Systems CVRx Lucid Diagnostics Pulmonx Profound Medical InfuSystem Orchestra BioMed iCAD Monogram Orthopaedics Amedica (NASDAQ:AMDA) and Pro-Dex (NASDAQ:PDEX) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, profitability, analyst recommendations, risk, valuation, institutional ownership, community ranking, earnings and media sentiment. Is AMDA or PDEX more profitable? Pro-Dex has a net margin of 11.06% compared to Amedica's net margin of -139.62%. Pro-Dex's return on equity of 21.68% beat Amedica's return on equity.Company Net Margins Return on Equity Return on Assets Amedica-139.62% -148.60% -67.83% Pro-Dex 11.06%21.68%12.40% Which has more risk and volatility, AMDA or PDEX? Amedica has a beta of -1.24, meaning that its stock price is 224% less volatile than the S&P 500. Comparatively, Pro-Dex has a beta of 0.37, meaning that its stock price is 63% less volatile than the S&P 500. Does the media refer more to AMDA or PDEX? In the previous week, Pro-Dex had 2 more articles in the media than Amedica. MarketBeat recorded 2 mentions for Pro-Dex and 0 mentions for Amedica. Pro-Dex's average media sentiment score of 1.26 beat Amedica's score of 0.00 indicating that Pro-Dex is being referred to more favorably in the news media. Company Overall Sentiment Amedica Neutral Pro-Dex Positive Do institutionals & insiders have more ownership in AMDA or PDEX? 3.7% of Amedica shares are owned by institutional investors. Comparatively, 15.3% of Pro-Dex shares are owned by institutional investors. 0.9% of Amedica shares are owned by insiders. Comparatively, 47.5% of Pro-Dex shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth. Does the MarketBeat Community prefer AMDA or PDEX? Amedica received 151 more outperform votes than Pro-Dex when rated by MarketBeat users. Likewise, 64.90% of users gave Amedica an outperform vote while only 61.90% of users gave Pro-Dex an outperform vote. CompanyUnderperformOutperformAmedicaOutperform Votes30764.90% Underperform Votes16635.10% Pro-DexOutperform Votes15661.90% Underperform Votes9638.10% Which has higher earnings and valuation, AMDA or PDEX? Pro-Dex has higher revenue and earnings than Amedica. Amedica is trading at a lower price-to-earnings ratio than Pro-Dex, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAmedica$11.23M2.97-$9.32M-$3.13-0.90Pro-Dex$64.12M2.32$2.13M$2.8016.29 Do analysts recommend AMDA or PDEX? Pro-Dex has a consensus price target of $52.00, indicating a potential upside of 13.99%. Given Pro-Dex's stronger consensus rating and higher probable upside, analysts clearly believe Pro-Dex is more favorable than Amedica.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Amedica 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Pro-Dex 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 SummaryPro-Dex beats Amedica on 15 of the 18 factors compared between the two stocks. Get Amedica News Delivered to You Automatically Sign up to receive the latest news and ratings for AMDA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart AMDA vs. The Competition Export to ExcelMetricAmedicaSurgical & Medical Instruments IndustryMedical SectorNASDAQ ExchangeMarket Cap$33.36M$4.43B$5.33B$8.39BDividend YieldN/A43.63%5.21%4.11%P/E Ratio-0.9029.0826.7319.70Price / Sales2.9770.54389.54120.67Price / CashN/A51.0838.2534.62Price / Book1.566.196.764.50Net Income-$9.32M$67.60M$3.23B$248.22M Amedica Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)AMDAAmedicaN/A$2.81-7.6%N/A+3,229.7%$33.36M$11.23M-0.90N/ANews CoverageGap DownHigh Trading VolumePDEXPro-Dex2.5748 of 5 stars$43.34+2.0%$52.00+20.0%+132.2%$141.33M$64.12M21.56140Positive NewsKRMDKORU Medical Systems2.3337 of 5 stars$3.01-6.2%$4.50+49.5%+22.0%$138.88M$35.08M-12.0480CVRXCVRx2.8408 of 5 stars$5.29-2.8%$14.50+174.1%-22.0%$137.84M$51.29M-1.97160LUCDLucid Diagnostics3.1878 of 5 stars$1.28+7.6%$3.50+173.4%+45.4%$134.89M$4.35M-1.1270Analyst DowngradeGap DownHigh Trading VolumeLUNGPulmonx3.2478 of 5 stars$3.26-1.8%$12.07+270.3%-65.1%$131.24M$87.47M-2.26250Analyst ForecastPROFProfound Medical2.5446 of 5 stars$4.04-5.4%$11.50+184.7%-35.4%$121.41M$10.68M-3.01150INFUInfuSystem2.4377 of 5 stars$5.73-0.3%$13.00+126.9%N/A$120.42M$137.58M95.52410OBIOOrchestra BioMed3.0369 of 5 stars$2.82-4.1%$14.20+403.5%-48.5%$108.04M$2.64M-1.754Gap UpICADiCAD0.3966 of 5 stars$3.91-0.5%N/A+133.8%$107.31M$19.61M-30.08140Analyst ForecastGap UpMGRMMonogram Orthopaedics3.0253 of 5 stars$2.50-3.5%$5.40+116.0%+31.0%$88.22M$364,999.00-5.3228Gap Up Related Companies and Tools Related Companies Pro-Dex Competitors KORU Medical Systems Competitors CVRx Competitors Lucid Diagnostics Competitors Pulmonx Competitors Profound Medical Competitors InfuSystem Competitors Orchestra BioMed Competitors iCAD Competitors Monogram Orthopaedics Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:AMDA) was last updated on 5/23/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredBuffett’s favorite chart just hit 209% – here’s what that means for goldA Historic Gold Announcement Is About to Rock Wall Street For months, sharp-eyed analysts have watched the ...Golden Portfolio | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredIs President Trump Lying To You With This?President Trump’s economic transition isn’t without hardship. But what if there were a smart, tax-free way to ...Colonial Metals | SponsoredJuly 2025 Rule Change to Impact Retirement InvestorsThere's a massive change from a new rule going into effect this July. And it's one the Big Banks are alread...Premier Gold Co | SponsoredTrump’s Bitcoin Reserve is No Accident…Bitcoin's supply is being drained at unprecedented rates, but while most investors focus solely on Bitcoin, th...Crypto 101 Media | SponsoredSilver Is the New Oil—And the World’s Running DryElon's Next Market Move Could Send Silver Soaring Every industry Elon Musk touches explodes—from Tesla to S...Priority Gold | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Amedica Co. Please log in to your account or sign up in order to add this asset to your watchlist. Share Amedica With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.